JP2024504392A5 - - Google Patents
Info
- Publication number
- JP2024504392A5 JP2024504392A5 JP2023544450A JP2023544450A JP2024504392A5 JP 2024504392 A5 JP2024504392 A5 JP 2024504392A5 JP 2023544450 A JP2023544450 A JP 2023544450A JP 2023544450 A JP2023544450 A JP 2023544450A JP 2024504392 A5 JP2024504392 A5 JP 2024504392A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- form iii
- section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163141789P | 2021-01-26 | 2021-01-26 | |
| US63/141,789 | 2021-01-26 | ||
| PCT/US2022/013953 WO2022164941A1 (en) | 2021-01-26 | 2022-01-26 | Advantageous morphic form of at-527 hemi-sulfate salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504392A JP2024504392A (ja) | 2024-01-31 |
| JP2024504392A5 true JP2024504392A5 (https=) | 2025-01-29 |
Family
ID=82653876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544450A Pending JP2024504392A (ja) | 2021-01-26 | 2022-01-26 | Ａｔ－５２７ヘミ硫酸塩の有利な形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230365611A1 (https=) |
| EP (1) | EP4284389A4 (https=) |
| JP (1) | JP2024504392A (https=) |
| KR (1) | KR20230135635A (https=) |
| CN (1) | CN116744939A (https=) |
| AU (1) | AU2022213335A1 (https=) |
| BR (1) | BR112023014825A2 (https=) |
| CA (1) | CA3173656A1 (https=) |
| IL (1) | IL304402A (https=) |
| MX (1) | MX2023008746A (https=) |
| TW (1) | TW202245806A (https=) |
| WO (1) | WO2022164941A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022213335A1 (en) * | 2021-01-26 | 2023-07-27 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Combination anti-HCV therapy is beneficial |
| WO2024211746A1 (en) * | 2023-04-06 | 2024-10-10 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Treatment of autoimmune diseases and cancer with protease inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| US20180214370A1 (en) * | 2017-01-31 | 2018-08-02 | L'oreal | Topcoat for long-wear lip compositions |
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| JP2022510014A (ja) * | 2018-12-05 | 2022-01-25 | アテア ファーマシューティカルズ， インコーポレイテッド | Ｃ型肝炎ウイルスの治療のための高活性な合剤 |
| US10874687B1 (en) * | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022213335A1 (en) * | 2021-01-26 | 2023-07-27 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
-
2022
- 2022-01-26 AU AU2022213335A patent/AU2022213335A1/en active Pending
- 2022-01-26 BR BR112023014825A patent/BR112023014825A2/pt unknown
- 2022-01-26 MX MX2023008746A patent/MX2023008746A/es unknown
- 2022-01-26 CN CN202280011806.3A patent/CN116744939A/zh active Pending
- 2022-01-26 WO PCT/US2022/013953 patent/WO2022164941A1/en not_active Ceased
- 2022-01-26 EP EP22746553.1A patent/EP4284389A4/en active Pending
- 2022-01-26 TW TW111103408A patent/TW202245806A/zh unknown
- 2022-01-26 KR KR1020237028660A patent/KR20230135635A/ko active Pending
- 2022-01-26 JP JP2023544450A patent/JP2024504392A/ja active Pending
- 2022-01-26 CA CA3173656A patent/CA3173656A1/en active Pending
-
2023
- 2023-07-11 IL IL304402A patent/IL304402A/en unknown
- 2023-07-25 US US18/226,064 patent/US20230365611A1/en active Pending
-
2025
- 2025-10-06 US US19/350,713 patent/US20260035404A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504392A5 (https=) | ||
| TWI788702B (zh) | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 | |
| ES2326529T3 (es) | Composicion farmaceutica que contiene una forma amorfa estabilizada de clorhidrato de donepezil. | |
| CN105646584B (zh) | 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途 | |
| JP2023524599A5 (https=) | ||
| JP2019509268A5 (https=) | ||
| CN101918418A (zh) | 替诺福韦地索普西的固体形式 | |
| CN1970547B (zh) | 非布司他的晶型及其制备方法 | |
| JP2012507496A (ja) | レナリドマイドの結晶形およびその調製方法 | |
| CN102002035A (zh) | 甲磺酸伊马替尼的δ和ε晶形 | |
| CN101633662A (zh) | 普拉格雷的药用酸加成盐及其制备方法和药物应用 | |
| TWI848241B (zh) | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物 | |
| CN101712692A (zh) | 泰诺福韦酯的药用酸加成盐及其制备方法和药物应用 | |
| US6717015B2 (en) | Venlafaxine besylate | |
| CN118161464A (zh) | 含阿司匹林的药物制剂及其制备方法和应用 | |
| JP2023536667A5 (https=) | ||
| RU2004127585A (ru) | Кристаллическая натриевая соль парекоксиба | |
| WO2016078543A1 (zh) | 一种盐酸洛氟普啶多晶型物及其制备方法 | |
| JP2010540470A5 (https=) | ||
| EP1844017A1 (en) | An amorphous and three crystalline forms of rimonabant hydrochloride | |
| JP2023548855A5 (https=) | ||
| CN104628708A (zh) | 一种阿伐那非的晶型及其制备方法、用途和药物组合物 | |
| JP2025511126A5 (https=) | ||
| SI22543A (sl) | Nove soli perindoprila | |
| WO2020161654A1 (en) | A process for the preparation of trametinib acetic acid solvate |